Coexistence of multiple sclerosis and brain tumors: a literature review.
DOI:
https://doi.org/10.26641/2307-0404.2020.2.206348Ключові слова:
multiple sclerosis, brain tumor, demyelinating diseases, glioma, astrocytoma, glioblastoma, oligodendrogliomaАнотація
Concurrent development of primary brain tumors and multiple sclerosis is quite rare. Only a few dozens of such comorbidity have been reported. Nevertheless, given the fact that such pathologies are characterized by similar clinical picture and neuroimaging findings, issues about diagnosis and differential diagnosis of such conditions often arise, which makes the problem relevant. A literature review was conducted using PubMed, by selecting articles on concurrent multiple sclerosis and brain tumors, particularly glial origin tumors, over the past 20 years (1989 to 2019). The search was performed in English, Russian, and Ukrainian using the following key words and terms: comorbidity, concomitance, multiple sclerosis, brain tumor, glioma, astrocytoma, glioblastoma. The analysis included all articles on etiology, pathogenesis, clinical picture, diagnosis, differential diagnosis, neuroimaging, and pathomorphological assessment. After identifying all the articles that met the inclusion criteria and removing duplicate data, 35 literature sources on concurrent primary brain tumors and multiple sclerosis were selected. The conclusion on whether concurrent primary brain tumors and multiple sclerosis develop randomly or have common pathophysiological mechanisms is still under discussion. Potential causes of pathogenesis of both diseases include viral infection, chronic inflammation, neoplastic transformation, and involvement of neurotropic growth factors. The likelihood that two processes, demyelinating and neoplastic, can develop in parallel will never be underestimated. In such cases, strong clinical suspicion arises due to atypical clinical picture characterized by aggressive and rapidly growing neurological symptoms such as aphasia, spastic hemiparesis, epileptic seizures, or signs of intracranial hypertension. In MRI diagnosis, pathological findings such as single lesion of more than 2 cm; mass effect, edema, signal amplification in the form of ring-shaped shadow are the reasons for a more thorough examination and applying additional diagnostic methods: CT, MR spectroscopy, PET, CSF tests to determine oligoclonal antibodies and other markers content, cerebral biopsy. According to the literature, cases of concurrent primary brain tumors and multiple sclerosis are rare though described. Atypical clinical signs, neuroimaging data, and cerebral biopsy which is currently considered as the only method for making accurate diagnosis are helpful in the diagnostic process.Посилання
Abdoli M, Freedman MS. Neuro-oncologydilemma: Tumour or tumefactive demyelinating lesion. Multiple Sclerosis and Related Disorders. 2015;4(6):22-30. doi: https://doi.org/10.1016/j.msard.2015.07.013
Abrishamchi F, Khorvash F. Coexistence of Multiple Sclerosis and Brain Tumor: An Uncommon Diagnostic Challenge. Advanced Biomedical Research. 2017:8-20. doi: https://doi.org/10.4103/abr.abr_625_13
Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. JAMA Oncol. 2016;4(1):22-10. doi: https://doi.org/10.1001/jamaoncol.2018.1789
Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022-4. doi: https://doi.org/10.1212/WNL.0000000000000768
Navarro S, Mondejar-Marin B, Pedrosa-Guerrero A, Perez-Molina I, Garrido-Robres JA, Alvarez-Tejerina A. Aphasia and parietal syndrome as the presenting symptoms of a demyelinating disease with pseudotumoral lesions. Rev Neurol. 2005;41(10):16-30. doi: https://doi.org/10.1016/j.jfo.2014.11.027
ASCO American Society of Clinical Oncology. Cancer. Net Editorial Board. 11/2017. Available from: https://www.cancer.net/cancer-types/brain-tumor/risk-factors/
Golombievski EE, McCoyd MA, Lee JM, Schneck MJ. Biopsy proven tumefactive multiple sclerosis with concomitant glioma: case report and review of the literature. Front Neurol. 2015;6:150. doi: https://doi.org/10.3389/fneur.2015.00150
Kalan Farmanfarma KH, Mohammadian M, Shahabinia Z, Hassanipour ., Salehiniya H. Brain cancer in the world: an epidemiological review. WCRJ. 2019;6:1356. doi: https://doi.org/10.32113/wcrj_20197_1356
Ferlay J, Seorjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2016. Available from: http://globocan.iarc.fr
Preziosa P, Sangalli F, Esposito F, Moiola L. Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. Neurol Sci. 2016;4:3-8. doi: https://doi.org/10.1007/s10072-016-2763-y
Sirko A, Dzyak L, Chekha E, Malysheva T, Romanukha D. Coexistence of multiple sclerosis and brain tumours: case report and review. Interdisciplinary Neurosurgery. 2019;4:8-18. doi:https://doi.org/10.1016/j.inat.2019.100585
Moisset X, Perié M, Pereira B, Dumont E, et al. Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study. Caspian Journal of Internal Medicine. 2017;8(3):172-7. doi: https://doi.org/10.1371/journal.pone.0188120
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria – The Lancet Neurology. 2017;6:50-64. doi: https://doi.org/10.1016/S0140-6736(18)30481-1
Dulamea A. Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis. Adv Exp Med Biol. 2017:91-127. doi: https://doi.org/10.1007/978-3-319-47861-6_7
Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffi etti R, Wick W. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15:395-403. doi: https://doi.org/10.1016/S1470-2045(14)70011-7
Montalban X, Gold R, Thompson AJ, Otero-Romero S, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal. 2018;24(2):96-120. doi: https://doi.org/10.1177/1352458517751049
Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Paris: Rev Neurol. 2016;172(1):3-13. doi: https://doi.org/10.1016/j.neurol.2015.10.006
Morales FS, Wright RB, Novo JE, Arvanitis LD, Stefoski D, Koralnik IJ. Glioblastoma in natalizumab-treated multiple sclerosis Patients. Annals of Clinical and Translational Neurology. 2017;4(7):512-16. doi: https://doi.org/10.1002/acn3.428
Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: A summary report and call to action. Ann Neurol. 2017;81(4):479-84. doi: https://doi.org/10.1002/ana.24897
Oh J, Ontaneda D, Azevedo C, et al. Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS. Neurology. 2019;2(20):88-102. doi: https://doi.org/10.1212/WNL.0000000000007099
Sun L‐M, et al. Increased breast cancer risk for patients with multiple sclerosis: a nationwide population‐based cohort study. Eur J Neurol. 2014;21(2):238-44. doi: https://doi.org/10.1111/ene.12267
Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F. MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. 2016;15(3):292-303. doi: https://doi.org/10.1016/S1474-4422(15)00393-2
Bakulin IS, Stoyda N., Askarova LSH, Konovalov RN. Multifocal central nervous system lymphoma misdiagnosed as acute disseminated encephalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8):95-102. doi: https://doi.org/10.17116/jnevro201811808295
Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. The Lancet. 2018;391(10130):10-36. doi: https://doi.org/10.1016/S0140-6736(18)30481-1
Carvalho TA, Linhares P, Castro L, Sá MJ. Multiple Sclerosis and Oligodendroglioma: An Exceptional Association. Case Rep Neurol Med. 2014;54681. doi: https://doi.org/10.1155/2014/546817
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, et al. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1. J Natl Compr Canc Netw. 2017;15(11):1331-45. doi: https://doi.org/10.6004/jnccn.2017.0166
Plantone D, Renna R. Concurrence of multiple sclerosis and brain tumors. Front Neurol. 2015;6:40. doi: https://doi.org/10.3389/fneur.2015.00040
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1-iv62.doi: https://doi.org/10.1093/neuonc/nov189
Ragonese P. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study. BMC Neurol. 2017;17(1):155. doi:https://doi.org/10.1186/s12883-017-0932-0
Dimitrov IN, Kaprelyan AG, Georgiev R, Ivanov BD. Rare clinical case of glioblastoma multiforme, multiple sclerosis and epilepsy: clinical, MRI and 18F-FDG PET study. J of IMAB. 2015;21(4):908-13. Available from: https://www.researchgate.net/publication/283784622_Rare_Clinical_Case_of_Glioblastoma_Multiforme_Multiple_Sclerosis_and_Epilepsy_Clinical_MRI_and_18FFDG_PET_Study
Wang X, Yang K, Wu Q, et al. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Science Translational Medicine. 2019;11(504):49-72. doi: https://doi.org/10.1126/scitranslmed.aau4972
Wallin MT, Culpepper WJ, Campbell JD, Lorene M, et al. The prevalence of MS in the United States. A population-based estimate using health claims data. AAN. 2019;92(10):165-290. doi: https://doi.org/10.1212/WNL.0000000000007035
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-20. doi: https://doi.org/10.1007/s00401-016-1545-1
Torensma R. Article The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage. Cancers. 2018;10(11):431. doi: https://doi.org/10.3390/cancers10110431
##submission.downloads##
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2020 Медичні перспективи
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.